Press coverage about Checkpoint Therapeutics (NASDAQ:CKPT) has been trending somewhat negative this week, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Checkpoint Therapeutics earned a news impact score of -0.04 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 49.4708576674408 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Checkpoint Therapeutics (NASDAQ:CKPT) traded down 0.8114% on Wednesday, reaching $6.1001. 8,987 shares of the company traded hands. The stock’s market capitalization is $154.75 million. Checkpoint Therapeutics has a one year low of $5.00 and a one year high of $15.00. The firm has a 50 day moving average of $7.49 and a 200-day moving average of $8.28.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.
Receive News & Ratings for Checkpoint Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.